Silver lake in talks to buy Workday (WDAY), deliberations ongoing, according to reports, citing sources
Newsquawk Staff ·
Silver lake in talks to buy Workday (WDAY), deliberations ongoing, according to reports, citing sources.
What it means
Silver Lake is among the most established technology-focused private equity sponsors, with a long record of large software take-privates and minority stakes, so a report of talks with Workday sits squarely within its historical hunting ground: mature, sticky-revenue enterprise software where public market multiples have compressed below what sponsors model as private value. Take-private chatter of this kind typically follows a familiar sequence: initial sourcing reports, a run-up in the target's shares toward an implied premium, then either confirmation with financing details or a denial that unwinds most of the move. The tell in software LBO reports of this vintage is the financing package and the multiple paid on recurring revenue, since sponsors in this space have historically leaned on subscription cash flows to support leverage. Workday's size puts any deal at the larger end of sponsor-led transactions, which raises questions about co-investors, syndication appetite in the leveraged loan and private credit markets, and antitrust scrutiny, though pure software combinations of this type have rarely drawn competition objections. Worth watching is whether the company confirms strategic review language, how Workday's activist and institutional shareholder base responds, and whether peer application software names re-rate on read-through, a pattern seen in past episodes of sponsor interest in the sector. As a sourced but unconfirmed report, the signal is directional rather than definitive.
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone
- Moderna (MRNA) downside attributed to early data leaks (link below) - UNCONFIRMED
- US EQUITY OPEN: Mag-7 earnings lead Tech and Indices lower as the Middle East situation remains fragile
- P&G (PG) CFO says expect materially higher cost headwinds in Q2 and second half of fiscal 2027 from higher oil prices
- US PREMARKET MOVERS: META, TSLA, IBM, LRCX, BX, PG, CMCSA, SAP, BABA
Related headlines
- State of Rhode Island sues Meta (META) over alleged tolerance for scam advertising2 hours ago
- Nvidia (NVDA) launches Minerva platform for end-to-end AI factory observability4 hours ago
- Meta's (META) 5yr CDS hits an all-time high at 114.5bps5 hours ago
- Google (GOOGL) is launching an agent compute engine6 hours ago
- US BROKER MOVES: CME upgraded at JPM; BROS downgraded at RBC 7 hours ago
- Comcast (CMCSA) Q3 2026 (USD): Adj. EPS 1.07 (exp. 0.99), Revenue 29.30bln (exp. 29.20bln)8 hours ago
- US President Trump called Musk and asked him to lift Ukraine Starlink (SPCX) restrictions, WSJ reports1 hour ago
- US President Trump says "Iran is doing everything they can to drive up the price of Oil prior to the U.S. Midterm Election". 3 hours ago
- Uber (UBER) puts all 30,000 employees on ChatGPT Work3 hours ago
- Newsquawk Daily US Earnings Estimates - 23rd October 2026: AXP3 hours ago
- Fireblocks denies talks with Visa (V), CoinDesk reports4 hours ago
- Norfolk Southern (NSC) says tightening truck capacity is improving rail competitiveness, supporting truck-to-rail conversions and stronger customer demand4 hours ago
- Procter & Gamble (PG) CFO says 'so far, consumer has held up, we don't know if that's going to continue'5 hours ago
- eBay (EBAY) confirms plans to reduce workforce by 9%; expects Q3 results above guidance 6 hours ago
- AbbVie (ABBV) announces positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa6 hours ago